Centessa Pharmaceuticals plc
CNTA
$16.08
-$0.73-4.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.01% | 9.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.62% | 60.72% | |||
| Operating Income | 58.73% | -60.72% | |||
| Income Before Tax | 77.57% | -162.83% | |||
| Income Tax Expenses | 33.05% | 72.70% | |||
| Earnings from Continuing Operations | 76.52% | -161.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 76.52% | -161.54% | |||
| EBIT | 58.73% | -60.72% | |||
| EBITDA | 58.97% | -60.81% | |||
| EPS Basic | 76.69% | -130.29% | |||
| Normalized Basic EPS | 67.78% | -56.85% | |||
| EPS Diluted | 76.69% | -130.29% | |||
| Normalized Diluted EPS | 67.78% | -56.85% | |||
| Average Basic Shares Outstanding | 0.74% | 13.59% | |||
| Average Diluted Shares Outstanding | 0.74% | 13.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||